#United States #Indianapolis #Lilly #Neuroscience #Anne White

Anne White Announces Retirement from Eli Lilly

Eli Lilly and Company has officially announced the upcoming retirement of Anne White, who has led the Lilly Neuroscience division for several years. Her retirement will become effective on December 31, 2025, concluding a remarkable career that spans three decades. During her tenure at Lilly, she has played a pivotal role in shaping the direction of the company, particularly in the areas of neurodegeneration, pain management, and psychiatric disorders.

David A. Ricks, chair and CEO of Lilly, praised White's formidable contributions during a recent statement, highlighting her deep commitment to devising effective treatments for some of the world's most challenging health issues. Under her leadership, Lilly made significant strides, including the development and launch of the company's first-ever Alzheimer's treatment. This milestone has been a game-changer in the realm of neurology, marking Lilly's proactive approach to tackling debilitating diseases.

Prior to her time in Neuroscience, Anne White was instrumental in Lilly's Oncology unit, where she contributed to the successful development of several late-stage products and facilitated the acquisition of Loxo Oncology, further expanding Lilly's oncology portfolio. Her strategic foresight and innovative thinking drove multiple projects from conception to market readiness, demonstrating her exceptional leadership qualities and deep understanding of the pharmaceutical landscape.

Anne's career has not only been about business achievements but also about championing diversity and inclusion within the workforce. She has served on the board of Lambda Legal and has received multiple accolades for her influence as a female leader in corporate America, including recognition from WomenInc. as one of the Most Influential Women Executives in the field.

In light of her upcoming retirement, Eli Lilly has launched an internal and external search to identify her successor. As they look to the future, many will be eager to see how the next leader will carry on the legacy of innovation and commitment to healthcare excellence that White has established.

Lilly's mission has always been to turn science into healing to improve lives globally. With a heritage of breakthrough research spanning nearly 150 years, the company has continually pushed the boundaries of what is possible in medicine. From developing solutions for diabetes and obesity to tackling challenging immune system disorders, Lilly's scientists remain dedicated to addressing some of the most significant health issues facing humanity.

Anne White leaves an indelible mark at Lilly as a leader who has garnered respect both within the company and across the industry. Her dedication to enhancing patient care and advocacy for underrepresented communities in healthcare has inspired both her colleagues and the broader public. As her departure approaches, the healthcare community reflects on her contributions and anticipates the next chapter for Lilly Neuroscience.

Her impact on healthcare and pharmaceutical innovation will be remembered, and her colleagues, friends, and the countless patients benefited by her work will undoubtedly miss her insights and leadership.